Insider buying last 90 days
No open-market insider purchases were filed for BHVN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BHVN insider filing, plotted on the chart in Gekko.Open BHVN in Gekko
NYSE: BHVN
Biohaven (BHVN) Stock Analysis & Forecast
Oct 12 close
$11.81−0.27 (−2.2%)
Gekko Brief
AI summaryOct 12 closeBiohaven's week centers on a regional licensing deal with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio, including BHV-1300, covering Japan, South Korea, Taiwan, and ASEAN countries. The agreement includes an $80 million upfront payment and a potential $20 million milestone, with royalties cited around 20% on net sales, and has been described as potentially worth up to $100 million. The news also notes fresh attention tied to an expanded oncology collaboration with Regeneron. Following the announcement, Raymond James reiterated a Strong Buy rating and a $30.00 price target on the stock.
Shares close at $11.81, down 2.2% on the day, sitting between the 50-day average of $13.89 and the 200-day average of $12.08. The one-month return stands at -7.1% and the three-month return at -21%, while six-month performance remains positive at 16.7%. The GekkoIndex reads 65.4, placing the stock in the Accumulation zone, up 4.2 over five days. Price sits 29.5% below the Gekko Fair Value of $16.75.
Biohaven's next earnings date falls on 9 November 2026, 28 days away, within a typical 20-trading-day holding window. The last quarter showed an EPS of -0.91 against a -0.77 estimate, with a -1.2% reaction, and the company has beaten estimates in 3 of its last 8 quarters, with an average absolute reaction of 5.9%. Seasonality from this point in the calendar has averaged a 4% gain over the next 20 trading days across 4 years, rising in 3 of them. No insider, Congress, or unusual options activity appears in the current window.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Biohaven price vs fair value
Close $11.81200-day averageGekko Fair Value $16.75
Biohaven quick facts
- Market cap
- $1.78B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.56
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 3.20
- Volume
- 1.62M avg 2.57M
- 1-year return
- −31.5%
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±13.1%
- 50-day average
- $13.89
- 200-day average
- $12.08
- Next earnings
- Nov 9
- Shares outstanding
- 151.0M
Biohaven swing-trade checklist
Biohaven scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $11.81 sits between the 50-day ($13.89) and 200-day ($12.08) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.4, Accumulation
Reading 65.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
29.5% below
Price is 29.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.0% on average
From this point in the calendar, the next 20 trading days averaged +4% over 4 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Biohaven stock chart and price history
Biohaven closed at $11.81 on Oct 12, 2026, −31.5% over the past year, inside a 52-week range of $7.48 to $18.57.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.1%
- 3 months
- −21.0%
- 6 months
- +16.7%
- 1 year
- −31.5%
The full BHVN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BHVN in Gekko
Follow Biohaven through every session
Put BHVN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BHVN in GekkoFree for 7 days. No credit card required.
About Biohaven
Biohaven works on medicines aimed at immune, brain-related, and cancer conditions, with programs that span autoimmune disorders, neurological disease, pain, metabolic conditions, and tumors. Its pipeline includes candidates in later-stage trials for Parkinson's disease and focal epilepsy, alongside other compounds being tested for conditions such as rheumatoid arthritis, kidney disease, obesity, and several cancer types.
Much of its work remains in clinical testing, with treatments at different trial phases targeting specific diseases, while a separate group of early-stage, preclinical compounds addresses further conditions including myasthenia gravis, nerve and kidney disorders, type 1 diabetes, and tinnitus. The company's activity centers on advancing this range of drug candidates toward potential approval rather than selling finished products.
The company is based in New Haven, Connecticut, and was incorporated in 2022, having previously operated under the name Biohaven Research Ltd. before adopting its current name later that year. Its shares are listed on the NYSE under the ticker BHVN.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- biohaven.com
Biohaven GekkoIndex: the smart money zone
Biohaven’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.4, in the Accumulation zone, up 4.2 points over five sessions.
65.4Accumulation
Up 4.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 54 | −0.1% | +1.7% | ||
| Accumulation (current zone) | 272 | +0.3% | −0.6% | ||
| Neutral | 335 | −1.1% | −3.3% | ||
| Distribution | 19 | +0.6% | +1.6% | ||
| Selling | 2 | Too few readings yet | |||
Average BHVN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the BHVN price, zone by zone.Track BHVN in Gekko
Is Biohaven stock overvalued? Gekko Fair Value
Biohaven trades 29.5% below Gekko Fair Value of $16.75, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Biohaven shares are worth, recalculated every trading day.
$16.75
Gekko Fair Value, Oct 9, 2026
29.5% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BHVN in Gekko
Biohaven insider and Congress trading
No open-market insider purchases were filed for Biohaven, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BHVN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BHVN, plotted on the chart in Gekko.Open BHVN in Gekko
Biohaven earnings: next date and track record
Biohaven reports on Nov 9, 2026 (28 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 9, 2026
28 days away
- EPS estimate
- −$0.61
- Revenue estimate
- $70.00M
3 of 8reports beat the EPS estimate
±5.9%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.91 est −$0.77 | — est $490K | −1.2% |
| May 4, 2026 | −$0.69 est −$0.76 | — est $267K | +0.8% |
| Mar 2, 2026 | −$0.90 est −$1.18 | — est $400K | −7.4% |
| Nov 10, 2025 | −$1.64 est −$1.91 | — est $375K | +3.1% |
| Aug 11, 2025 | −$1.94 est −$1.94 | — est $413K | −8.6% |
| May 12, 2025 | −$2.17 est −$1.67 | — | −3.6% |
| Mar 3, 2025 | −$1.71 est −$1.60 | — | −15.6% |
| Nov 12, 2024 | −$1.74 est −$1.70 | — | −6.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Biohaven stock forecast and analyst price targets
Analysts’ average 12-month price target for Biohaven is $21.27, +80.1% from the last close, from 11 firms rating the stock in the last 90 days.
$21.27consensus 12-month target, +80.1% from the last close
Now $11.81Avg $21.27
Low $10High $30
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Bank of America Securities | $11 | −6.9% |
| Oct 9 | Canaccord Genuity | $21 | +77.8% |
| Sep 30 | Canaccord Genuity | $21 | +77.8% |
| Sep 17 | Citi | $17 | +43.9% |
| Sep 13 | J.P. Morgan | — | — |
−0.6%average 20-day move after past Accumulation readings
+4.0%average move over the next 20 trading days in the last 4 years
±6.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Biohaven seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Biohaven averaged +4.0% across the last 4 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.7% | 3 of 4 |
| Next 10 trading days | +11.9% | 4 of 4 |
| Next 15 trading days | +15.1% | 3 of 4 |
| Next 20 trading days | +4.0% | 3 of 4 |
| Next 30 trading days | −0.8% | 2 of 4 |
For scale, BHVN’s typical 20-trading-day move in either direction is about 13.1%.
Biohaven market cap and key statistics
Biohaven’s market cap is $1.78B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.78B
- EPS, TTM
- −$4.56
- Gekko Fair Value
- $16.75
Trading
- Volume
- 1.62M
- Avg volume, 20 days
- 2.57M
- 52-week high
- $18.57
- 52-week low
- $7.48
- Shares outstanding
- 151.0M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -799%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 3.20
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±13.1%
Biohaven stock news this week
Coverage of Biohaven this week reads positive: 8 positive, 2 neutral and 0 negative headlines.
- Ono Pharmaceutical (TSE:4528) Secures Biohaven Asia Rights, Is The Stock Still A Bargain?Simply Wall Street, Oct 12
- How Biohaven Licensing Deal At Ono Pharmaceutical Stock Has Changed Its Investment StorySimply Wall Street, Oct 9
- Biohaven partners with Ono in $100m IgG degrader dealPharmaceutical Technology, Oct 9
- Biohaven (BHVN), What Is Behind The Fresh Attention?Simply Wall Street, Oct 8
- Biohaven Licenses IgG Degrader Portfolio to Ono for $80 Million UpfrontBigGo Finance, Oct 8
- Biohaven Expands Asian Licensing Footprint Through Strategic Ono AgreementBenzinga, Oct 8
Biohaven peers
Biohaven’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Biohaven stock FAQ
What is Biohaven’s market cap?
Biohaven’s market cap is $1.78B at the Oct 12, 2026 close of $11.81, with 151.0M shares outstanding.
What is the Biohaven stock forecast?
The consensus analyst 12-month price target for Biohaven is $21.27, +80.1% from the last close. Of the 11 firms that rated the stock in the last 90 days, 7 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Biohaven stock overvalued or undervalued?
On Gekko’s estimate Biohaven is undervalued: the Oct 12, 2026 close of $11.81 is 29.5% below Gekko Fair Value of $16.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Biohaven report earnings next?
Biohaven is expected to report on Nov 9, 2026 (28 days away). Analysts expect earnings of −$0.61 per share on revenue of $70.00M. Biohaven beat the earnings estimate in 3 of its last 8 reports, moving 5.9% on average across the report.
What is Biohaven’s 52-week high and low?
Biohaven’s 52-week high is $18.57 and its 52-week low is $7.48; it closed at $11.81 on Oct 12, 2026, −31.5% over the past year. Over the last five years the shares peaked at $62.21 on Mar 8, 2024.
Is Biohaven stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Biohaven the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.